Cell cycle checkpoint kinase (CHK)1 inhibition induces immune modulation in recurrent BRCA wild-type high-grade serous ovarian cancer (HGSOC) patients

被引：0
|
作者：
Lampert, Erika J. [1 ]
Lee, Min-Jung [1 ]
Trepel, Jane B. [1 ]
Yuno, Akira [1 ]
Cimino-Mathews, Ashley [2 ]
Lee, Joo-Sang [1 ]
Ruppin, Eytan [1 ]
Nair, Jayakumar [1 ]
Ekwede, Irene [1 ]
Lee, Jung-Min [1 ]
机构：
[1] NCI, Ctr Canc Res, Bethesda, MD 20892 USA
[2] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.SABCS18-5000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5000
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Correlative biomarker analysis of the phase II study of prexasertib, a cell cycle checkpoint kinase 1 (CHK1) inhibitor, in BRCA wild-type (BRCAwt), platinum-resistant recurrent, high-grade serous ovarian cancer (PR-HGSOC)
    Giudice, Elena
    Zurcher, Grant
    Nair, Jayakumar
    Huang, Tzu-Ting
    Lee, Min-Jung
    Trepel, Jane B.
    Lee, Jung-Min
    CANCER RESEARCH, 2023, 83 (07)
  • [2] Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints
    Ivy, S. Percy
    Kunos, Charles A.
    Arnaldez, Fernanda I.
    Kohn, Elise C.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (09) : 771 - 785
  • [3] Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
    Lee, Jung-Min
    Nair, Jayakumar
    Zimmer, Alexandra
    Lipkowitz, Stanley
    Annunziata, Christina M.
    Merino, Maria J.
    Swisher, Elizabeth M.
    Harrell, Maria J.
    Trepel, Jane B.
    Lee, Min-Jung
    Bagheri, Mohammad H.
    Botesteanu, Dana-Adriana
    Steinberg, Seth M.
    Minasian, Lori
    Ekwede, Irene
    Kohn, Elise C.
    LANCET ONCOLOGY, 2018, 19 (02): : 207 - 215
  • [4] Prexasertib, a cell cycle checkpoint kinase 1 inhibitor, in BRCA mutant recurrent high-grade serous ovarian cancer (HGSOC): A proof-of-concept single arm phase II study.
    Lampert, Erika Joelle
    An, Daniel
    McCoy, Ann
    Kohn, Elise C.
    Annunziata, Christina M.
    Trewhitt, Kathryn
    Zimmer, Alexandra Dos Santos
    Lipkowitz, Stanley
    Lee, Jung-min
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] BRCA1 methylation status in high-grade serous ovarian cancer (HGSOC) patients (pts).
    Ruscito, Ilary
    Braicu, Elena Ioana
    Panici, Pierluigi Benedetti
    Chekerov, Radoslav
    Dimitrova, Desislava
    Ganapathi, Ram N.
    Vasconcelos, Ines
    Bellati, Filippo
    Fotopoulou, Christina
    Lichtenegger, Werner
    Olek, Sven
    Sehouli, Jalid
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses
    Lampert, Erika J.
    Cimino-Mathews, Ashley
    Lee, Joo Sang
    Nair, Jayakumar
    Lee, Min-Jung
    Yuno, Akira
    An, Daniel
    Trepel, Jane B.
    Ruppin, Eytan
    Lee, Jung-Min
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [7] The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial
    Giudice, Elena
    Huang, Tzu-Ting
    Nair, Jayakumar R.
    Zurcher, Grant
    Mccoy, Ann
    Nousome, Darryl
    Radke, Marc R.
    Swisher, Elizabeth M.
    Lipkowitz, Stanley
    Ibanez, Kristen
    Donohue, Duncan
    Malys, Tyler
    Lee, Min-Jung
    Redd, Bernadette
    Levy, Elliot
    Rastogi, Shraddha
    Sato, Nahoko
    Trepel, Jane B.
    Lee, Jung-Min
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [8] Combined inhibition of checkpoint kinase 1 (CHK1) and phosphoinositide 3-kinase (PI3K) pathways induces greater replication stress and DNA damage in high-grade serous ovarian cancer (HGSOC)
    Huang, Tzu-Ting
    Nair, Jayakumar
    Brill, Ethan
    Zhang, Xiaohu
    Wilson, Kelli
    Chen, Lu
    Thomas, Craig J.
    Lee, Jung-Min
    CANCER RESEARCH, 2020, 80 (16)
  • [9] Use of Gynecologic Cancer Intergroup (GCIG) CA125 criteria to evaluate cell cycle checkpoint kinase 1 inhibitor (CHK1i) prexasertib response and disease progression (PD) in recurrent high-grade serous ovarian cancer (HGSOC)
    Ibanez, Kristen
    Donohue, Duncan
    Malys, Tyler
    Lee, Jung-Min
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Morphological feature discrepancies in wild-type vs. BRCA1/BRCA2 mutated high-grade serous ovarian cancer
    Lee, JaeHeon
    Kim, Hyunil
    Lee, Yongeun
    Choi, Yoon-La
    Jung, Kyungsoo
    Kwak, Tae-Yeong
    Kim, Sun Woo
    Chang, Hyeyoon
    CANCER RESEARCH, 2024, 84 (06)
12345